Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Wainberg, Zev A., Hochster, Howard S., Kim, Edward J., George, Ben, Kaylan, Aparna, Chiorean, E. Gabriela, Waterhouse, David M., Guiterrez, Martin, Parikh, Aparna, Jain, Rishi, Carrizosa, Daniel Ricardo, Soliman, Hatem H., Lila, Thomas, Reiss, David J., Pierce, Daniel W., Bhore, Rafia, Banerjee, Sibabrata, Lyons, Larry, Louis, Chrystal U., Ong, Teng Jin, O'Dwyer, Peter J. · 2020 · Clinical Cancer Research

Abstract

Purpose: Assess safety and efficacy of nivolumab plus nab-paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial. Patients and Methods: Fifty chemotherapy-naive patients received nab-paclitaxel 125 mg/m2 plus gemcitabine 1,000 mg/m2 (days 1, 8, and 15) and nivolumab 3 mg/kg (days 1 and 15) in 28-day cycles. The primary endpoints were dose-limiting toxicities (DLTs; part 1) and grade 3/4 treatment-emergent adverse events (TEAEs) or treatment discontinuation due to TEAEs (parts 1/2). Secondary efficacy endpoints were progression-free survival (PFS), overall survival (OS), and response. Assessment of programmed cell death-ligand 1 (PD-L1) expression was an exploratory endpoint; additional biomarkers were assessed post hoc. Results: One DLT (hepatitis) was reported in part 1 among six DLT-evaluable patients; 48 of 50 patients experienced grade 3/4 TEAEs and 18 discontinued treatment due to TEAEs. One grade 5 TEAE (respiratory failure) was reported. Median [95% confidence interval (CI)] PFS/OS was 5.5 (3.25–7.20 months)/9.9 (6.74–12.16 months) months, respectively [median follow-up for OS, 13.6 months (95% CI, 12.06–23.49 months)]. Overall response rate (95% CI) was 18% (8.6%–31.4%). Median PFS/OS was 5.5/9.7 months (PD-L1 <5%) and 6.8/11.6 months (PD-L1 ≥5%), respectively. Proportion of peripheral Ki67+ CD8+/CD4+ cells increased significantly from baseline to cycle 3; median peak on-treatment Ki67+ CD8+ T-cell values were higher in responders than in nonresponders. Conclusions: The safety profile of nivolumab plus nab-paclitaxel and gemcitabine at standard doses in advanced pancreatic cancer was manageable, with no unexpected safety signals. Overall, the clinical results of this study do not support further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-0099

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 158

Metadata

Authors
Wainberg, Z. A., Hochster, H. S., Kim, E. J., George, B., Kaylan, A., Chiorean, E. G., Waterhouse, D. M., Guiterrez, M., Parikh, A., Jain, R., Carrizosa, D. R., Soliman, H. H., Lila, T., Reiss, D. J., Pierce, D. W., Bhore, R., Banerjee, S., Lyons, L., Louis, C. U., Ong, T. J., & O'Dwyer, P. J.
Venue
Clinical Cancer Research
Published
2020-09-15
Volume
26
Issue
18
Pages
4814-4822
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3036393903
Cited by
158
References
17
FWCI
6.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-0099
The paper
Wainberg, Z. A., Hochster, H. S., Kim, E. J., George, B., Kaylan, A., Chiorean, E. G., Waterhouse, D. M., Guiterrez, M., Parikh, A., Jain, R., Carrizosa, D. R., Soliman, H. H., Lila, T., Reiss, D. J., Pierce, D. W., Bhore, R., Banerjee, S., Lyons, L., Louis, C. U., . . . O'Dwyer, P. J. (2020). Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-0099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.